GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Angelalign Technology Inc (HKSE:06699) » Definitions » Intrinsic Value: Projected FCF

Angelalign Technology (HKSE:06699) Intrinsic Value: Projected FCF : HK$0.00 (As of Dec. 13, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Angelalign Technology Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-12-13), Angelalign Technology's Intrinsic Value: Projected FCF is HK$0.00. The stock price of Angelalign Technology is HK$58.05. Therefore, Angelalign Technology's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Angelalign Technology's Intrinsic Value: Projected FCF or its related term are showing as below:

HKSE:06699's Price-to-Projected-FCF is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.72
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Angelalign Technology Intrinsic Value: Projected FCF Historical Data

The historical data trend for Angelalign Technology's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Angelalign Technology Intrinsic Value: Projected FCF Chart

Angelalign Technology Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial - - - - -

Angelalign Technology Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Angelalign Technology's Intrinsic Value: Projected FCF

For the Medical Instruments & Supplies subindustry, Angelalign Technology's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Angelalign Technology's Price-to-Projected-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Angelalign Technology's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Angelalign Technology's Price-to-Projected-FCF falls into.



Angelalign Technology Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Angelalign Technology  (HKSE:06699) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Angelalign Technology's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=58.05/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Angelalign Technology Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Angelalign Technology's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Angelalign Technology Business Description

Traded in Other Exchanges
Address
No. 500 Zhengli Road, 6th Floor - 7th Floor, Building No. 7, KIC Business Center, Yangpu District, Shanghai, CHN
Angelalign Technology Inc is an investment holding company. It is principally engaged in clear aligner treatment solutions including treatment planning services, manufacturing, and marketing of clear aligners. The company provides dental professionals with self-developed digital orthodontics solutions. The company's Angelalign clear aligner system facilitates dental professionals throughout the entire clear aligner treatment process, including digitally-assisted case assessment support and treatment planning services, provide dental professionals with digitally-assisted case assessment support and treatment planning services, and helps dental professionals design, review and modify treatment plans.
Executives
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Carecapital Dental Holdings Limited 2201 Interest of corporation controlled by you
Morgan Stanley 2201 Interest of corporation controlled by you
Carecapital Ea, Inc 2201 Interest of corporation controlled by you
Carecapital Management Group Llc 2201 Interest of corporation controlled by you
Carecapital Moonstone Holdings Limited 2201 Interest of corporation controlled by you
Feng Dai 2201 Interest of corporation controlled by you
Shore Lead Limited 2201 Interest of corporation controlled by you
Sky Honour Enterprises Limited 2101 Beneficial owner
Li Huamin 2307 Founder of a discretionary trust who can infl
Carecapital Orthotech Limited 2101 Beneficial owner
Chen Kai 2201 Interest of corporation controlled by you
Jovial Day Global Limited 2201 Interest of corporation controlled by you
Vast Luck Global Limited 2101 Beneficial owner
Xing Zheng Quan Qiu Ji Jin Guan Li You Xian Gong Si 2102 Investment manager

Angelalign Technology Headlines

No Headlines